KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.96

Baseline tumor burden predicts the efficacy of first-line chemoimmunotherapy in patients with advanced non-small cell lung cancer: results from 2 phase 3 randomized placebo-controlled trials.

Xinyi He, Mengting Shi, Lin Zhang, Jianhua Zhan, Jiaqing Liu, Dongchen Sun, Zihong Chen, Shaodong Hong, Yaxiong Zhang, Gang Chen, Shen Zhao, Ting Zhou, Wenfeng Fang, Yuanyuan Zhao, Yan Huang, Caicun Zhou, Yunpeng Yang, Li Zhang, Huaqiang Zhou

BMC Cancer 25(1) 1380

PMID40866864
PMCIDPMC12382186
DOI10.1186/s12885-025-14755-z
发表日期2025-08-27
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
摘要

摘要

BACKGROUND: Baseline tumor burden (TB), measured radiographically, has emerged as a potential biomarker for stratifying survival outcomes with immune checkpoint inhibitors (ICI) across solid tumors. However, the predictive value for ICI plus chemotherapy (chemoimmunotherapy) in NSCLC has not been confirmed with large cohorts that include a chemotherapy-only control group. METHODS: This post hoc analysis utilized data from ORIENT-11 trial, a phase III, randomized clinical trial of advanced NSCLC patients who were administered with either chemoimmunotherapy or chemotherapy alone. TB was measured as the sum of the diameters of target lesions at baseline following RECIST 1.1 criteria. The relationships between baseline TB and outcomes were assessed using the Cox proportional hazards model. Validation was conducted using data from ORIENT-12 trial. RESULTS: In chemoimmunotherapy arm, patients with low TB demonstrated longer progression-free survival (PFS: 11.60 vs. 7.20 months, hazard ratio [HR] = 0.625, p = 0.004) and overall survival (OS: 28.77 vs. 20.10 months, HR = 0.683, p = 0.020) compared to those with high TB. In the chemotherapy-only arm, no significant survival differences were observed based on TB levels. Multivariate analyses confirmed that regardless of tumoral PD-L1 expression, low TB as an independent marker of improved survival with chemoimmunotherapy. Patients with high TB and low PD-L1 expression had the shortest survival, deriving minimal benefit from chemoimmunotherapy over chemotherapy alone (PFS: 5.53 vs. 5.07 months; OS: 10.52 vs. 13.80 months). These findings were validated in ORIENT-12 cohort. CONCLUSIONS: Baseline TB is a predictive, rather than prognostic, clinical biomarker for survival outcomes in advanced NSCLC patients treated with chemoimmunotherapy. TB assessment, integrated with PD-L1 status evaluation, may improve patient stratification for first-line chemoimmunotherapy in clinical practice and provide valuable insight for the clinical trials designs.

KM 提取结果

2 个 Figure · 10 个 KM 面板

进入结果中心
KM Figure6 个面板

Fig. 1

Fig. 1 Survival outcomes of NSCLC patients treated with chemoimmunotherapy or chemotherapy. A , B Kaplan–Meier PFS ( A ) and OS ( B ) curves of NSCLC patients treated with chemoimmunotherapy (combo) stratified by TB. C, D Kaplan–Meier PFS ( C ) and OS ( D ) curves of NSCLC patients treated with chemotherapy (chemo) stratified by TB. E, F Kaplan–Meier PFS ( E ) and OS ( F ) curves of patients stratified by assigned treatment and TB, and the results of subgroup analyses. Abbreviation: Chemo, chemotherapy; CI, confidence interval; Combo, chemoimmunotherapy; HR, hazard ratio; NSCLC, non-small cell lung cancer; OS, overall survival; PFS, progression-free survival; TB, tumor burden

A

PFS

Fig. 1 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

OS

Fig. 1 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

PFS

Fig. 1 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:short span
查看结果
D

OS

Fig. 1 · Panel D

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel D 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
E

PFS

Fig. 1 · Panel E

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel E 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
F

OS

Fig. 1 · Panel F

quality_warning 待 EXE 对齐 预期 4 条 已提取 3 条

Panel F 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线缺失:预期 4 条,实际恢复 3 条疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线 3:off origin start
查看结果
KM Figure4 个面板

Fig. 3

Fig. 3 Survival outcomes of patients stratified by TB and PD-L1 expression. A, B Kaplan–Meier PFS ( A ) and OS ( B ) curves of NSCLC patients treated with chemoimmunotherapy stratified by TB and PD-L1 TPS (≥ 1%/< 1%). C, D Kaplan–Meier PFS ( C ) and OS ( D ) curves of NSCLC patients treated with chemotherapy stratified by TB and PD-L1 TPS (≥ 1%/< 1%). Abbreviation: CI, confidence interval; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; PD-L1, programmed death-ligand 1; TB, tumor burden; TPS, tumor proportional score

A

PFS

Fig. 3 · Panel A

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel A 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme upward reversal曲线 3:extreme upward reversal
查看结果
B

OS

Fig. 3 · Panel B

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel B 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal曲线 4:extreme upward reversal
查看结果
C

PFS

Fig. 3 · Panel C

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel C 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal曲线 3:extreme upward reversal曲线 4:extreme upward reversal
查看结果
D

OS

Fig. 3 · Panel D

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel D 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme upward reversal
查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 2Fig. 2 Multivariate Cox regression analyses of survival outcomes of NSCLC patients. A, B Forest plots showing the results of multivariate Cox regression analyses of PFS ( A ) and OS ( B ) in NSCLC patients receiving chemoimmunotherapy. C, D Forest plots showing the results of multivariate Cox regression analyses of PFS ( C ) and OS ( D ) in NSCLC patients receiving chemotherapy. Abbreviation: BMI, body-mass index; Chemo, chemotherapy; CI, confidence interval; Combo, chemoimmunotherapy; ECOG PS, ECOG, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; NSCLC, non-small cell lung cancer; OS, overall survival; PD-L1, programmed death-ligand 1; PFS, progression-free survival; TB, tumor burden; TPS, tumor proportional score
非 KM Figure